Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEAN-RAPHAEL R SCHNEIDER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1487691127
CMS profile
249229
Location
CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$16,862.02

217 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEAN-RAPHAEL R SCHNEIDER

NPI 1487691127 · CMS profile ID 249229

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487691127?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEAN-RAPHAEL R SCHNEIDER, NPI 1487691127, CMS profile ID 249229. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487691127?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JEAN-RAPHAEL R SCHNEIDER, NPI 1487691127, CMS profile ID 249229. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487691127?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JEAN-RAPHAEL R SCHNEIDER, NPI 1487691127, CMS profile ID 249229, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1487691127?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

217 matching records · $16,862.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 217 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 217.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $25.7904/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987071337 CMS
Biogen, Inc. $19.2804/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012148397 CMS
EMD Serono, Inc. $22.0704/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032521909 CMS
Acorda Therapeutics, Inc $21.4604/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1005344187 CMS
Novartis Pharmaceuticals Corporation $16.1304/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993256945 CMS
BANNER LIFE SCIENCES, LLC $24.5004/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021110273 CMS
ARGENX US, INC. $1,425.0004/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060427111 CMS
Alnylam Pharmaceuticals Inc. $29.5704/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006145217 CMS
PFIZER INC. $23.3104/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050630947 CMS
AbbVie Inc. $26.0204/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998867009 CMS
AbbVie Inc. $14.3804/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998867005 CMS
Novartis Pharmaceuticals Corporation $12.4104/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993256943 CMS
Genentech USA, Inc. $21.0304/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040392591 CMS
Biogen, Inc. $22.1104/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012173131 CMS
Celgene Corporation $26.0304/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015300893 CMS
PFIZER INC. $17.9904/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050441681 CMS
IMPEL PHARMACEUTICALS INC. $20.9103/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989381135 CMS
Biogen, Inc. $20.1703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012231885 CMS
Alexion Pharmaceuticals, Inc. $24.0003/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017005583 CMS
Novartis Pharmaceuticals Corporation $19.1503/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993256941 CMS
EMD Serono, Inc. $22.0703/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032455823 CMS
EMD Serono, Inc. $20.2103/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032484279 CMS
Horizon Therapeutics plc $25.3203/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987071335 CMS
AbbVie Inc. $27.4603/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998867001 CMS
AbbVie Inc. $19.2903/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998866997 CMS
CSL Behring $15.5603/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042896141 CMS
Novartis Pharmaceuticals Corporation $22.3903/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993256955 CMS
Celgene Corporation $27.7603/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015300851 CMS
PFIZER INC. $17.4503/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050529957 CMS
BANNER LIFE SCIENCES, LLC $24.7603/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021108979 CMS
Novartis Pharmaceuticals Corporation $26.7703/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993256953 CMS
Otsuka America Pharmaceutical, Inc. $18.7503/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014791985 CMS
Genentech USA, Inc. $22.4902/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040392613 CMS
Amylyx Pharmaceuticals, Inc. $15.5202/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057679093 CMS
Novartis Pharmaceuticals Corporation $24.6602/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993256951 CMS
Biogen, Inc. $25.2602/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012281049 CMS
Lundbeck LLC $22.8302/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032348963 CMS
BANNER LIFE SCIENCES, LLC $24.0302/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021108685 CMS
GENZYME CORPORATION $31.2502/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050015251 CMS
ARGENX US, INC. $32.4402/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060427059 CMS
AbbVie Inc. $29.3802/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998866993 CMS
ARGENX US, INC. $791.3802/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060427117 CMS
Grifols USA, LLC $23.2802/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011787071 CMS
Novartis Pharmaceuticals Corporation $23.8502/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993256947 CMS
TG THERAPEUTICS, INC. $38.0002/09/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051476043 CMS
TG Therapeutics, Inc. $23.6802/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051476053 CMS
IMPEL PHARMACEUTICALS INC. $21.4902/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989381141 CMS
PFIZER INC. $15.6302/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050576789 CMS
Celgene Corporation $25.3002/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015300827 CMS
AbbVie Inc. $16.7702/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998866989 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $80,532.16 244
PY2020 $17,258.79 201
PY2021 $15,732.24 222
PY2022 $24,018.05 228
PY2023 $16,862.02 217
PY2024 $24,262.82 227
PY2025 $39,887.72 237

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $421,658.88 45
PY2024 Principal investigator $573,984.19 31
PY2023 Principal investigator $425,295.33 31
PY2022 Principal investigator $602,220.97 35
PY2021 Principal investigator $460,918.62 27
PY2020 Recipient $129.92 1
PY2020 Principal investigator $374,459.26 18
PY2019 Recipient $2,491.26 10
PY2019 Principal investigator $101,900.00 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Hoffmann-La Roche Limited $1,062.00 12/16/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211626518
Principal investigator 1 Hoffmann-La Roche Limited $52.50 12/01/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211626514
Principal investigator 1 Hoffmann-La Roche Limited $250.00 12/01/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211626522
Principal investigator 1 TG Therapeutics, Inc. $25,000.00 11/30/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200807
Principal investigator 1 Genentech, Inc. $200.00 11/18/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626561
Principal investigator 1 Genentech, Inc. $5,418.00 11/06/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626565
Principal investigator 1 TG Therapeutics, Inc. $125.00 11/04/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200812
Principal investigator 1 TG Therapeutics, Inc. $12,025.00 11/01/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200805
Principal investigator 1 Genentech, Inc. $100.00 10/08/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626549
Principal investigator 1 TG Therapeutics, Inc. $150.00 10/01/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200809
Principal investigator 1 TG Therapeutics, Inc. $10,100.00 09/30/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200789
Principal investigator 1 Genentech, Inc. $11,710.00 09/19/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626557
Principal investigator 1 Genentech, Inc. $10,233.00 09/18/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626554
Principal investigator 1 GENZYME CORPORATION $2,452.50 09/15/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226117294
Principal investigator 1 Alexion Pharmaceuticals, Inc. $500.00 09/04/2025 Non-covered Recipient Entity
MS AND NEUROMUSCULAR CENTER OF EXCELLENCE
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185547079
Principal investigator 1 TG Therapeutics, Inc. $3,850.00 08/31/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200787
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,630.88 08/19/2025 Non-covered Recipient Entity
MS AND NEUROMUSCULAR CENTER OF EXCELLENCE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190305769
Principal investigator 1 TG Therapeutics, Inc. $75.00 08/04/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200791
Principal investigator 1 Genentech, Inc. $292.00 08/01/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626544
Principal investigator 1 TG Therapeutics, Inc. $4,025.00 07/31/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200785
Principal investigator 1 Genentech, Inc. $192.00 07/29/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626540
Principal investigator 1 GENZYME CORPORATION $316.00 07/28/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226117283
Principal investigator 1 GENZYME CORPORATION $11,522.90 07/28/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226117289
Principal investigator 1 GENZYME CORPORATION $2,600.00 07/02/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226117278
Principal investigator 1 Genentech, Inc. $600.00 06/10/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626528
Principal investigator 1 TG Therapeutics, Inc. $8,175.00 06/01/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200719
Principal investigator 1 TG Therapeutics, Inc. $200.00 05/31/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200721
Principal investigator 1 GENZYME CORPORATION $3,780.00 05/19/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226117266
Principal investigator 1 GENZYME CORPORATION $4,292.10 05/19/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226117271
Principal investigator 1 TG Therapeutics, Inc. $3,525.00 05/01/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200725
Principal investigator 1 Genentech, Inc. $19,005.00 04/15/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626537
Principal investigator 1 GENZYME CORPORATION $1,000.00 04/02/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226117253
Principal investigator 1 GENZYME CORPORATION $1,762.50 04/02/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226117258
Principal investigator 1 Genentech, Inc. $542.00 04/02/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626535
Principal investigator 1 TG Therapeutics, Inc. $1,300.00 03/31/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200727
Principal investigator 1 TG Therapeutics, Inc. $900.00 03/20/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200723
Principal investigator 1 TG Therapeutics, Inc. $3,500.00 02/28/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200729
Principal investigator 1 Hoffmann-La Roche Limited $52.00 02/06/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211626573
Principal investigator 1 Genentech, Inc. $100.00 02/05/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626532
Principal investigator 1 TG Therapeutics, Inc. $10,600.00 02/01/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200731
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,464.25 01/28/2025 Non-covered Recipient Entity
MS AND NEUROMUSCULAR CENTER OF EXCELLENCE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190310038
Principal investigator 1 GENZYME CORPORATION $10,450.00 01/21/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226117246
Principal investigator 1 TG Therapeutics, Inc. $15,175.00 01/06/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200733
Principal investigator 1 Hoffmann-La Roche Limited $250.50 01/02/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211626568
Principal investigator 1 Novartis Pharmaceuticals Corporation $210,103.75 01/01/2025 Non-covered Recipient Entity
MS AND NEUROMUSCULAR CENTER OF EXCELLENCE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190305771